In Houston, you can get the most house for the buck among the country's biggest metro areas. Photo by TK Images

In Houston, you can get the most house for the buck among the country's biggest metro areas, a new study shows.

The study, recently published by Austin-based online insurance marketplace The Zebra, indicates you can purchase a 1,935-square-foot home in the Houston metro area at the U.S. median sale price. In 2019, that price was $239,900, according to Zillow data analyzed by The Zebra.

The study calculated how much square footage you can afford in the 10 largest metros in the U.S., based on Zillow's calculations for median home price per square foot.

In 2019, the median price of a single-family home in the Houston area was $245,800, up from $238,800 in 2018, according to the National Association of Realtors. A record 86,205 single-family homes were sold across the Houston area in 2019, up 4.8 percent from the previous record of 82,229 in 2018, the Houston Association of Realtors says.

"It's great to see Houston at the top of this study, as the Bayou City has been one of the most of the most affordable cities in the United States," says Paige Martin, leader of the Houston Properties Team at Keller Williams Realty. "The Houston metro area is adding more residents each year than the entire population of Pittsburgh. A big reason for that is the cost of living is so much lower than other major cities in the U.S."

In terms of large houses, Martin continues to see high demand for bigger properties from a lot of homebuyers, particularly millennials and Generation Y members.

"These homebuyers typically grew up in smaller homes than what they're seeking now," she says, "and they're drawn to the benefits of every child having their own bedroom, designated play areas, and large and expansive kitchens for family gatherings and entertainment."

"Fortunately, Houston can accommodate this," Martin adds, "as the city is blessed with so many top-ranked suburbs that have low land costs."

Meanwhile, Dallas is No. 3 on the list. In 2019, the median price of a single-family home in Dallas-Fort Worth was $268,000, up from $260,000 the previous year, according to the National Association of Realtors. In a report covering January 2020, the MetroTex Association of Realtors said year-over-year sales of single-family homes were up 21 percent, while the total dollar volume climbed 32 percent to nearly $1.98 billion.

In December, Realtor.com predicted home prices in Dallas-Fort Worth would decline 0.5 percent this year compared with 2019.

"The North Texas housing market has come off of several record-breaking years," Cathy Mitchell, 2019 president of the MetroTex Association of Realtors, said in December. "A slight self-correction in the market compared to what we have experienced the last few years was expected and could prove to be beneficial in balancing our market with more quality inventory."

In The Zebra's study, here's how the mega-metros stack up in terms of how much square footage you can purchase at the U.S. median home price:

1. Houston, 1,935 square feet
2. Atlanta, 1,817 square feet
3. Dallas-Fort Worth, 1,726 square feet
4. Philadelphia, 1,589 square feet
5. Chicago, 1,463 square feet
6. Miami, 1,043 square feet
7. Washington, D.C., 1,012 square feet
8. Boston, 789 square feet
9. Los Angeles, 540 square feet
10. New York City, 361 square feet

"New York, L.A., and Boston may not be enough elbow room for you, but Houston, Atlanta, and Dallas will get you the most bang for your buck," The Zebra says.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."